Adjunct Faculty

Barry Berkowitz, Ph.D.

University of California, San Francisco. Adjunct Professor of Pharmacology. Founder, Chairman, and Chief Executive Officer, Strong Pharma, LLC. Strong has founded several companies including: Myco/ChemGenics, Fibrogen and New Chemical Entities (sold to Albany Molecular). Strong is currently organizing a new company which utilizes a compelling and novel business model to increase the efficiency of and accelerate drug development.

Dennis W. Choi, M.D., Ph.D.

Harvard University/Harvard Medical School, Boston, MA. Adjunct Professor of Pharmacology. Professor and Chair, Department of Neurology and Director of the Neuroscience Institute, Stony Brook University, Stony Brook, NY. Dr. Choi oversees the development of four key areas: neuroscience education, behavioral neuroscience and cognition, brain therapeutics, and molecular and translational imaging research.

Ruth E. Gimeno, Ph.D.

Massachusetts Institute of Technology. Adjunct Associate Professor of Pharmacology. Chief Scientific Officer, Diabetes Drug Hunting Team, Eli Lilly and Company, Indianapolis, IN.
Research Interests: Development of novel therapeutics for obesity and type 2 diabetes. Areas of interest include appetite regulation,insulin resistance and energy expenditure, and pancreatic beta cell function.

Marion Kasaian, Ph.D.

Case Western Reserve University. Adjunct Associate Professor of Pharmacology. Principal Research Scientist IV, Inflammation and Immunology, Pfizer Global Biotherapeutic Technologies, Pfizer, Inc., Cambridge, MA.
Research interests: Cellular and innate immune mechanisms contributing to inflammatory diseases, with a focus on asthma.

John C. McKew, Ph.D.

University of California, Davis. Adjunct Associate Professor of Pharmacology.   Chief, Therapeutics Development Branch, Center for Translational Therapeutics, National Institutes of Health, Bethesda, MD.
Research Interests:Research interests include medicinal chemistry, synthetic methodology and tool compounds to probe biology. This research has been directed against targets in Inflammation, Cardiovascular, Metabolic Disease, and Muscle Biology.

Steven M. Paul, M.D., B.A.

Tulane University. Adjunct Professor of Pharmacology. Director of the Helen and Robert Appel Alzheimer’s Disease Research Institute and Professor of Neurology (Neuroscience) and Psychiatry, Weill Cornell Medical College, New York, NY.
Research Interests: Mechanisms of action of centrally acting pharmacologic agents, neurotransmitters, and hormones.

Steven Projan, Ph.D.

Columbia University. Adjunct Professor of Pharmacology, Vice President, Senior Vice President, R & D, Innovative Medicines and Head of Infectious Diseases & Vaccines at MedImmune, Gaithersburg, MD.
Research Interests: Drug discovery and development, antibiotic resistance, and bacterial virulence.

Carl E. Rosow, M.D., Ph.D.

Oberlin College; M.D. Boston University School of Medicine, Ph.D. Boston University. Adjunct Associate Professor of Pharmacology, School of Medicine; Professor of Anaethesia, Harvard Medical School.
Research Interests: the pharmacokinetics and pharmacodynamics of opioids and sedative hypnotic drugs.

Robert G. Schaub, Ph.D.

Washington State University. Adjunct Professor of Pharmacology. Chief Scientific Officer, NKT Therapeutics, Inc., Waltham, MA.
Research Interests:Current research interests are directed to two areas: one is on the role of platelets and leukocytes in the pathophysiology of peripheral circulatory disease and thrombosis. The other is the identification of new treatments for coagulation deficiencies like hemophilia A, hemophilia B and other rare bleeding disorders.

Bryan K. Yamamoto, Ph.D.

Syracuse University. Adjunct Professor of Pharmacology. Professor and Chairman, Neurosciences Department, University of Toledo.

Research Interests:A primary research focus is in neuropharmacology and is related to the neurotoxicity of the amphetamines, particularly methamphetamine and MDMA (Ecstasy).

Cara M. M. Williams, Ph.D.

University of Liverpool.

Adjunct Associate Professor of Pharmacology. Director of Translational Pharmacology, Inflammation and Remodeling Research Unit, Pfizer Biotherapeutics R & D in Cambridge, Massachusetts.

Clive Wood, Ph.D.

Imperial College, London. Adjunct Professor of Pharmacology. Senior Vice President and Head, Global Biologics, Global Drug Discovery, Bayer Schering Pharma AG in Wuppertal, Germany;

Discovery and preclinical development of innovative therapeutics for inflammation and oncology. Current areas of focus include antibody and small protein-based inhibitors of proteases.